Navigation Links
Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
Date:9/23/2009

ent or investigator.

Ron Bentsur, CEO of Keryx Biopharmaceuticals, stated, "We are very excited about this long-term data for Zerenex. The study suggests that Zerenex can maintain patients within the normal serum phosphorous range for extended periods of time and that the drug appears to be well-tolerated." Mr. Bentsur added, "We are also very encouraged by the emerging data suggesting that Zerenex may reduce the need for IV iron or EPO in this dialysis patient population, and should the results be replicated in the upcoming Phase 3 program, this could represent a significant clinical and cost advantage to the patient and the doctor."

ABOUT HYPERPHOSPHATEMIA

In the United States, according to data from the U.S. Renal Data System, there are approximately 485,000 patients with end-stage renal disease, or ESRD, and the number of ESRD patients is projected to rise 60% to approximately 785,000 by 2020. The majority of ESRD patients, over 350,000, require dialysis. Phosphate retention and the resulting hyperphosphatemia in patients with ESRD on dialysis are usually associated with secondary hyperparathyroidism (and its related cardiovascular complications), renal osteodystrophy and soft tissue mineralization. ESRD patients usually require treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. The need for alternative phosphate-binding agents has long been recognized, especially given the increasing prevalence of ESRD as well as shortcomings with current therapies. Zerenex has the potential to be an effective and safe treatment in lowering and/or maintaining normal serum phosphorus levels in patients with ESRD and hyperphosphatemia.

The market for phosphate binders to treat hyperphosphatemia in ESRD patients in the U.S. exceeded $600 million in 2008, and has grown approximately 25% per annum over the last five years.

ABOUT KERY
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
10. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 Today, a group of national medical ... H.R. 3590, the Patient Protection and Affordable Care Act, ... its way towards a final vote in the coming ... Senators to vote against a health care bill that ... first hand that our health care system needs reform ...
(Date:12/16/2009)... WORTH, Texas, Dec. 16 Wound ... a rapidly growing provider of specialty medical ... operating subsidiary is moving toward productization of ... The company currently anticipates products to be ... market, estimated to be a multi-billion dollar ...
(Date:12/16/2009)... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an online U.S. ... in 12% per annum short term debt financing. ... drawdown of $500,000, with accrued interest and principal repayable ... accrued interest and principal repayable in one year from ... positive for any calendar month prior to December 15, ...
Breaking Medicine Technology:Physician Groups Oppose Current Senate Health Care Reform Bill 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 3HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2Recondo Technology Introduces New Software Service for Hospitals 53761 1Recondo Technology Introduces New Software Service for Hospitals 53761 2ADVENTRX Pharmaceuticals Announces Financing 13392 1ADVENTRX Pharmaceuticals Announces Financing 13392 2ADVENTRX Pharmaceuticals Announces Financing 13392 3ADVENTRX Pharmaceuticals Announces Financing 13392 4MaxLife Fund Corp announces cancellation of 14 050 000 Common Shares 53754 1MaxLife Fund Corp announces cancellation of 14 050 000 Common Shares 53754 2
... Suppresses Amyloid Plaque Formation, ANNAPOLIS, Md., April ... biodefense company specializing in the development,and commercialization ... announced today that new data from its,recombinant ... the 8th International Conference on,Alzheimer's and Parkinson's ...
... Vitro Assays Show rBChE Suppresses Amyloid Plaque,Formation ... PharmAthene, Inc., a leading,biodefense company specializing in ... chemical and,biological terrorism, announced today that new ... were,recently presented at the 8th International Conference ...
Other Medicine Technology:PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
(Date:12/17/2009)... selected Jay and Maureen Neitz, the husband-and-wife team whose ... therapy to treat vision disorders, as the inaugural recipients ... , The award is funded by a $1 million ... graduates Jay Pepose ,75 and Susan K. Feigenbaum ,74, ... in vision science. , The Neitzes, both of whom ...
(Date:12/17/2009)... particle might someday ease accompanying lung infections , , THURSDAY, ... pneumonia when infected with the swine flu virus, and ... , A key to the severity of the illness ... which helps the immune system fight off germs and ... swine-flu patients at 10 Spanish hospitals last summer found ...
(Date:12/17/2009)... Scientific Studies Important ,for the R&D Informatics Industry, , ... ... -- Cambridge Healthtech Institute is pleased to announce the participation ... Adopting R&D Informatics Systems conference to be held on February ... Francisco, CA. This meeting has been integrated in the Informatics ...
(Date:12/17/2009)... Dec. 17 It,s customary for the holidays ... any busy time of year, workouts often get short-changed ... to celebrity fitness trainer Valerie Waters, it is not ... the window. That,s why California Raisins and Waters have ... wise choices during the holiday season and get a ...
(Date:12/17/2009)... The recently opened Laser Spine ... the community in full force this holiday season, as ... 13th, benefiting the Arthritis Foundation, a non-profit organization dedicated ... event boasted 1,500 attendees, spotlighting LSI,s passion for their ... renowned, national fundraiser and a festive way to get ...
Breaking Medicine News(10 mins):Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3Health News:Celebrity Fitness Trainer Valerie Waters and California Raisins Offer Advice on How to Jump Start the New You in the New Year 2Health News:Celebrity Fitness Trainer Valerie Waters and California Raisins Offer Advice on How to Jump Start the New You in the New Year 3Health News:Laser Spine Institute (LSI) Supports Jingle Bell Run 2
... today,s scientific program of the 2008 Joint Meeting of ... of Ophthalmology (SOE) include a study that correlates optic ... and potentially elevated risk for stroke, and a survey ... to the world,s seven major religions, may affect patient ...
... older age and high weight gain, are known ... pressure disorders. Now a new report suggests that ... increase the risk of pre-eclampsia and pregnancy-induced hypertension ... American Society of Nephrology,s 41st Annual Meeting and ...
... Cataract Surgery Patients can Better Understand Their Condition at CataractSurgery.com ... ... Cataract surgery patients and their caregivers now have a new online ... . Cataracts affect nearly 20 million Americans age 60 ...
... Nov. 7 Ninety years ago today,the guns fell silent ... all wars" -,was over. Almost five million Americans served during ... 107-year-old Army veteran,Frank Buckles, observes this Veterans Day at his ... Day, for all Americans to reflect on the,service and sacrifice ...
... stress fractures, experts say, , , FRIDAY, Nov. 9 (HealthDay News) ... strengthen bones in older women. These vital nutrients may also ... , To illustrate that point, many bone health experts refer ... Navy recruits that found that women who didn,t take additional ...
... After playing a,pivotal role in helping turn around the ... Mogel, President and Chief Executive,Officer of Integrated Healthcare Holdings, ... of IHHI. He will continue to serve,as Chief Executive ... December 31, 2008., "In his four years with ...
Other Medicine News:Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 2Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 3Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 4Health News:Rural women are at higher risk of blood pressure disorders during pregnancy 2Health News:Alcon Sponsors Online Educational Initiative for Patients Considering Cataract Surgery 2Health News:A Veterans Day Message From VA Secretary Dr. James B. Peake 2Health News:A Veterans Day Message From VA Secretary Dr. James B. Peake 3Health News:A Veterans Day Message From VA Secretary Dr. James B. Peake 4Health News:Active Young Women Need Calcium, Vitamin D 2Health News:Active Young Women Need Calcium, Vitamin D 3Health News:Chief Executive Officer Leaving Integrated Healthcare Holdings, Inc. 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: